Indian pharma company in pact with Swiss firm to sell 7 generic drugs in Singapore, Thailand

  • 📰 staronline
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 75%

United Kingdom News News

United Kingdom United Kingdom Latest News,United Kingdom United Kingdom Headlines

MUMBAI/SINGAPORE (Xinhua): India's Biocon Pharma and Swiss Market Expansion Services Group DKSH on Monday (June 22) have entered into a collaboration wherein the latter will sell and distribute seven of Biocon's generic formulations in Singapore and Thailand, a Biocon statement said.

As part of the agreement, Zurich headquartered DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand.

"This collaboration will enable us to address the growing patient needs for affordable access to high-quality generics for chronic diseases and expand our commercial footprint in this region," said Siddharth Mittal, CEO & Managing Director, Biocon, with annual revenues of 837.5 million U.S. dollars. "Together with Biocon Pharma, we can help a lot of patients in Asia who require advanced therapies for chronic diseases."

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 4. in UK
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Indian company launches drug to treat mild, moderate Covid-19 patients; another gunfight breaks out in KashmirMUMBAI (Xinhua): Glenmark Pharmaceuticals has become the first Indian company to launch anti-viral drug Favipiravir for the treatment of mild to moderate Covid-19 patients in the domestic market following the manufacturing approval from the drug regulator, a company statement said.
Source: staronline - 🏆 4. / 75 Read more »